HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...
Lung cancer is the leading cause of cancer death worldwide. It is classified according to cell of origin into small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC), the latter ...
The American College of Chest Physicians (CHEST) recently released a new clinical guideline on the management of patients with early-stage non-small cell lung cancer (NSCLC). Published in the journal ...
Sequential therapy strategies in oncogene-driven NSCLC. This figure illustrates a proposed therapeutic decision-making pathway for patients with NSCLC who develop acquired resistance after initial ...
The KRAS p.G12D variant occurs in 5% of patients with non–small-cell lung cancer (NSCLC) and is the most common substitution variant in pancreatic ductal adenocarcinoma, occurring in 40% of patients, ...
Adherence to quality metrics in early-stage NSCLC improves outcomes, but disparities exist among certain demographics, highlighting the need for equitable healthcare practices. Cemiplimab plus ...
Zacks Investment Research on MSN
BDTX: What silevertinib data say about EGFR NSCLC upside
Black Diamond Therapeutics, Inc. BDTX is building its equity story around a single, high-leverage asset: silevertinib, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) ...
RMAT designation requires preliminary clinical evidence addressing an unmet need in a serious disease and provides Fast Track/Breakthrough-like advantages, including frequent FDA interactions and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results